Researchers have shown that ritanserin is a novel DGK-alpha inhibitor, with activity against glioblastoma (GBM) in vitro and in vivo. They have shown that it is synergistic with temozolomide chemotherapy and radiation against GBM cells. Furthermore, ritanserin has preferential cytotoxicity against mesenchymal GBM cells, a particularly treatment-resistant subset lacking any selective and effective therapies at this time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!